Search Results 261-270 of 708 for ������������������������ ������������KaKaotalk:PC53���24������ ���������������

  1. Long-Term Safety of PF-00547659 in Ulcerative Colitis - Mayo Clinic

    Subjects with Ulcerative Colitis who have completed an induction study with PF-00547659 will receive an additional 72 weeks of open-label treatment to evaluate ...

  2. Combination Chemotherapy in Treating Young Patients With Newly Diagnosed High-Risk B Acute Lymphoblastic Leukemia and Ph-Like TKI Sensitive Mutations - Mayo Clinic

    This randomized phase III trial studies how well combination chemotherapy works in treating young patients with newly diagnosed B acute lymphoblastic leukemia ...

  3. Phase 1b Clinical Trial to Evaluate PEP and EUFLEXXA for Knee Osteoarthritis (KOA)

    Rochester, Minnesota: 24-008843; Scottsdale/Phoenix, Arizona: 24-008843. NCT ID: NCT06463132. About this study. The purpose of this study is to evaluate the ...

  4. A Multicenter Study of the Effectiveness and Safety of JZP-258 in the Treatment of Idiopathic Hypersomnia (IH) with an Open-label Safety Extension - Mayo Clinic

    The purpose of this study istoevaluate the effectiveness and safety of JZP-258, an oxybate mixed-salts oral solution being developed as a low sodium alternative ...

  5. Mayo Clinic Q & A - Dr. Gregory Poland - COVID- 19 Update Tra...

    Our thanks to Mayo Clinic infectious disease and virology expert, Dr. Greg Poland. Thanks so much Dr. Poland. Dr. Gregory Poland 24:46. My pleasure. DeeDee.

  6. Novel cholangiopancreatoscope with a large rotating channel for pancreatobiliary disorders - Mayo Clinic

    The study will recruit patients undergoing ERCP with diagnostic and therapeutic interventions as part of routine clinical care for pancreaticobiliary diseaseTo ...

  7. Health Topics - Mayo Clinic News Network

    On this week's episode of Tomorrow's Cure, we explore brain-computer interfaces (BCIs), cutting-edge technologies that create direct communication pathways ...

  8. A Study To Evaluate The Efficacy And Safety Of Tulisokibart (MK-7240) In Participants With Moderate To Severe Crohn's Disease (MK-7240-008) - Mayo Clinic

    Rochester, Minnesota: 24-008233. NCT ID: NCT06430801. Sponsor Protocol Number: Protocol Number: 008-00. About this study. The purpose of this protocol is to ...

  9. Publications

    AN UNUSUAL CAUSE OF HYPERCALCEMIA AND NEPHROCALCINOSIS DURING PREGNANCY-CYP24A1 DEFICIENCY AMERICAN JOURNAL OF KIDNEY DISEASES (Vol. 85, No. 4). 2025. Kizilbash ...

  10. A Phase 1b/2a Multicenter, Open-Label, Dose-Escalation Study to Determine the Maximum Tolerated Dose, Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of CC-220 as Monotherapy and in Combination with Other Treatments in Subjects with Multiple Myeloma - Mayo Clinic

    CC-220-MM-001: A Phase 1b/2a Multicenter, Open-Label, Dose-Escalation Study to Determine the Maximum Tolerated Dose, Assess the Safety, Tolerability, ...